Literature DB >> 11236950

Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers.

C Thiede1, M Bornhäuser, U Oelschlägel, C Brendel, R Leo, H Daxberger, B Mohr, M Florek, F Kroschinsky, G Geissler, R Naumann, M Ritter, G Prange-Krex, T Lion, A Neubauer, G Ehninger.   

Abstract

Sequential analysis of chimerism after allogeneic blood stem cell transplantation (BSCT) has been shown to be predictive for graft failure and relapse. We have explored the impact of a novel approach for the quantitative determination of chimerism using a commercial PCR assay with multiplex amplification of nine STR-loci and fluorescence detection. The feasibility was studied in 121 patients transplanted from related or unrelated donors. Follow-up investigation was performed in 88 patients. Twenty-eight of these patients had received a transplantation after dose-reduced conditioning therapy. Results were compared to data obtained by FISH analysis in a subgroup of patients receiving grafts from sex-mismatched donors. The analysis was possible in all patients, the median number of informative alleles was 4 (range 1-8) compared to 7 (range 1-9) in the related and unrelated situation, respectively. A good correlation was seen in 84 samples from 14 patients analyzed in parallel with STR-PCR and FISH. Decreasing values of donor chimerism were detected prior to or concomitantly with the occurrence of graft failure and relapse of disease in all patients investigated prospectively. Using FACS-sorted material, eg peripheral blood CD34+ cells, the assay permitted the detection of residual recipient cells with high sensitivity (down to one CD34+ Kasumi cell in 40,000 normal WBC). Evaluation of the inter-laboratory reproducibility revealed that in 20 samples analyzed in three different centers, the median coefficient of variation was 2.1% (range 0.7-9.6%). Taken together, the results support the use of the test as a valuable tool in the follow-up of patients undergoing allogeneic BSCT. In cases lacking PCR-detectable disease-specific gene products, this assay may represent an alternative to recently established real-time PCR methods.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11236950     DOI: 10.1038/sj.leu.2401953

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  25 in total

1.  Feasibility of a cost-effective approach to evaluate short tandem repeat markers suitable for chimerism follow-up.

Authors:  Ariela F Fundia; Carlos De Brasi; Irene Larripa
Journal:  Mol Diagn       Date:  2004

2.  Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation.

Authors:  Scott R Solomon; Stephan Mielke; Bipin N Savani; Aldemar Montero; Laura Wisch; Richard Childs; Nancy Hensel; John Schindler; Victor Ghetie; Susan F Leitman; Thao Mai; Charles S Carter; Roger Kurlander; Elizabeth J Read; Ellen S Vitetta; A John Barrett
Journal:  Blood       Date:  2005-04-07       Impact factor: 22.113

3.  Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation.

Authors:  Martin Bornhäuser; Uta Oelschlaegel; Uwe Platzbecker; Gesine Bug; Karin Lutterbeck; Michael G Kiehl; Johannes Schetelig; Alexander Kiani; Thomas Illmer; Markus Schaich; Catrin Theuser; Brigitte Mohr; Cornelia Brendel; Axel A Fauser; Stefan Klein; Hans Martin; Gerhard Ehninger; Christian Thiede
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

4.  Bone marrow engraftment analysis after granulocyte transfusion.

Authors:  Sharon L Swierczynski; Michael J Hafez; Juliet Philips; Meghan A Higman; Karin D Berg; Kathleen M Murphy
Journal:  J Mol Diagn       Date:  2005-08       Impact factor: 5.568

5.  Capillary electrophoresis artifact due to eosin: implications for the interpretation of molecular diagnostic assays.

Authors:  Kathleen M Murphy; Karin D Berg; Tanya Geiger; Michael Hafez; Katie A Flickinger; Lisa Cooper; Patrick Pearson; James R Eshleman
Journal:  J Mol Diagn       Date:  2005-02       Impact factor: 5.568

6.  Prognostic utility of routine chimerism testing at 2 to 6 months after allogeneic hematopoietic cell transplantation.

Authors:  Ghada I Mossallam; Azza M Kamel; Barry Storer; Paul J Martin
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

7.  Lack of utility of chimerism studies obtained 2-3 months after myeloablative hematopoietic cell transplantation for ALL.

Authors:  Kc Doney; Mr Loken; Em Bryant; Ag Smith; Fr Appelbaum
Journal:  Bone Marrow Transplant       Date:  2008-05-26       Impact factor: 5.483

8.  Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies.

Authors:  Federico Moscardó; Jaime Sanz; Leonor Senent; Susana Cantero; Javier de la Rubia; Pau Montesinos; Dolores Planelles; Ignacio Lorenzo; Jose Cervera; Javier Palau; Miguel A Sanz; Guillermo F Sanz
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

Review 9.  Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.

Authors:  P Tsirigotis; M Byrne; C Schmid; F Baron; F Ciceri; J Esteve; N C Gorin; S Giebel; M Mohty; B N Savani; A Nagler
Journal:  Bone Marrow Transplant       Date:  2016-06-13       Impact factor: 5.483

10.  Hematopoietic chimerism monitoring based on STRs: quantitative platform performance on sequential samples.

Authors:  Don Kristt; Moshe Israeli; Ronit Narinski; Hagit Or; I Yaniv; Jerry Stein; Tirza Klein
Journal:  J Biomol Tech       Date:  2005-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.